Interactions of GLP-1, GIP, and GCGR Agonists - Suggesting Potential Treatments for Metabolic Disorders and Obesity

Oct 13, 2026

The intricate interplay among glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors (GCGR) is examined to explain how regulatory networks maintain metabolic homeostasis. The study integrates molecular biology, physiology, and nutritional science to evaluate combined receptor activation effects on appetite control, insulin sensitivity, and energy metabolism. Results indicate synergistic pathway activation reduces appetite, improves insulin responsiveness, and increases energy expenditure, supporting therapeutic targets for obesity and type 2 diabetes. It reviews receptor pharmacology, FDA-approved therapies, and investigational GLP-1 pathway agonists, including dual- and triple-action agents.

LanguageEnglish

CategoryForms

FormatPDF

Pages32

Reading Time11 min

AccessFree to download

Abstract

Keywords

Abbreviation

Introduction

Glucagon-like Peptide-1 (GLP-1)

GLP-1 metabolism

GLP-1 effects on satiety and weight

GLP-1 receptor agonists and liver metabolism

| World Journal of Diabetes & Metabolism
Genesis-WJDM-1(1)-01 Volume 1 | Issue 1 |2026
| | | --- | --- | | Interactions of GLP-1, GIP, and GCGR Agonists, Suggesting Potential Treatments for Metabolic Disorders and Obesity
Alber Fares1*, George Fares2 and Peter Fares3
1 Professor of Medical Biochemistry and Genetics at Xavier University School of Medicine at Aruba
2 Intern Pharmacist, Advent Health, East Orlando, Florida, USA
3 University of Central Florida (UCF), School of Health Science
*Corresponding author: Alber Fares, Professor of Medical Biochemistry and Genetics at Xavier University School of Medicine at Aruba | | | Citation: Fares A, Fares G, Fares P. Interactions of GLP- 1, GIP, and GCGR Agonists, Suggesting Potential Treatments for Metabolic Disorders and Obesity. World J Diabetes Metab. 1(1):1-32.
Received: July 08, 2026 | Published: July 20, 2026 | Copyright© 2026 Genesis Pub by Fares A, et al. This isan open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4. 0) . This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are properly credited. | |
Abstract
The intricate interplay among glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors (GCGR) is a focal point in understanding the regulatory networks that govern metabolic homeostasis. These peptide hormones, each with unique receptor-mediated pathways, converge to orchestrate a multifaceted response that influences appetite control, enhances insulin sensitivity, and optimizes energy expenditure. This study explores the combined effects of GLP-1, GIP, and GCGR receptor activation on metabolic parameters critical to maintaining energy balance and glucose homeostasis. Using a comprehensive approach integrating molecular biology, physiology, and nutritional science, we investigated how these receptors collectively modulate appetite, insulin sensitivity, and energy metabolism. Our findings reveal that the synergistic activation of these pathways results in a significant reduction in appetite, improved insulin responsiveness, and increased energy expenditure. These findings suggest potential therapeutic targets for tackling metabolic disorders such as obesity and type 2 diabetes. The study covers GLP-1, GIP, and GCGR receptor pharmacology and therapeutic uses, including FDA-approved treatments and those in development for GLP-1 receptor agonists, dual-action GIP/GLP-1 receptor agonists, and triple-action GLP-1, GIP, and GCGR receptor agonists. The review underscores the importance of a holistic understanding of hormonal interactions in developing effective metabolic interventions.
Keywords
Diabetes mellitus type 2; Glucagon-like Peptide-1 (GLP-1), Glucose-dependent Insulinotropic Polypeptide (GIP), and Glucagon Receptor (GCGR); Hypothalamus; Incretins; Obesity; Satiation; Central nervous system. | | | | | Abbreviation GLP-1: Glucagon-like Peptide-1; GIP: Glucose-dependent Insulinotropic Polypeptide; GCGR: Glucagon receptor; T2DM: type 2 diabetes mellitus; GLP1Rs: GLP-1 receptors; DPP-4: dipeptidyl peptidase-4; GLP- 1Ras: GLP-1 receptor agonists; WAT: white adipose tissue; AT: adipose tissue; BAT: while brown adipose tissue; ARC: hypothalamic arcuate nucleus; DMN: the dorsomedial nucleus; cAMP-PKA: AMP-protein kinase A; VMN: the ventromedial nucleus; T2D: type 2 diabetes; POMC: Pro-opiomelanocortin, a vital precursor protein and gene involved in the melanocortin; CART: Cocaine-and Amphetamine-Regulated Transcript; MC3: Melanocortin-3 Receptor; MC4R: Melanocortin-4 Receptor; MC3: Melanocortin-3 Receptor; MC4R: Melanocortin-4 Receptor; NPY: Neurons producing neuropeptide Y; AgRP: agouti-related peptide; FDA: U.S. Food and Drug Administration; EMA: European Medicines Agency; GPCRs: G proteincoupled receptors; ALT: alanine aminotransferase. In

FAQs

How do GLP-1, GIP, and GCGR interactions relate to metabolic homeostasis?

They coordinate receptor-mediated pathways that influence appetite control, insulin sensitivity, and energy expenditure, supporting balanced glucose regulation and metabolic stability.

What main effects does the combined activation of these pathways produce?

Synergistic activation is reported to reduce appetite, improve insulin responsiveness, and increase energy expenditure, indicating potential benefits for metabolic disorders.

Which therapeutic approaches for GLP-1 signaling are discussed?

The review covers GLP-1 receptor pharmacology and therapeutic uses, including FDA-approved treatments and agents in development such as GLP-1 receptor agonists, dual-action GIP/GLP-1 agonists, and triple-action GLP-1/GIP/GCGR agonists.

Oct 13, 2026

Upload by 4398046744996